The DOI matches its Crossref record; 183 of the 184 references it cites were found in a registry or an index.
Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies
Open accessAbstract
receptor 2 (apoER2), sortilin-related receptor (SorLA/ LR11), LRP5, and LRP6.These receptors have distinct physiological or pathophysiolgical roles, likely due to differences in their affinity to ligands, protein stability, endocytosis rate, signaling potency, cellular localization, and tissue expression pattern.While these receptors bind diverse extracellular ligands, some of them recognize key molecules in the pathogenesis of Alzheimer's disease (AD), such as apoE and amyloid- peptides (As) for cellular trafficking and/or signaling pathways.Given that the 4 allele of the APOE gene (APOE4) is the strongest genetic risk factor for AD among the three human alleles (2, 3, and 4), the potential contributions of LDLR family members to AD development have attracted great interest by many laboratories around the world for over two decades (1, 2).Cumulative evidence from preclinical studies using cellular or animal studies indicates that LDLR family members can contribute to AD pathogenesis through modulating A accumulation or neurodegenerative processes.However, as there are currently no complete cellular or animal models that can recapitulate all pathological features of AD, parallel understanding between cellular/animal studies and human studies is necessary to define the specific role of any molecule in AD pathogenesis.Herein, among the LDLR family members, we comprehensively discuss the roles of LRP1 in AD pathogenesis by reviewing both preclinical studies using cellular/animal models, and clinical studies analyzing human samples/cohorts.We will specifically review current knowledge regarding: 1) LRP1 expression during AD progression, 2) contribution of Abstract Among the LDL receptor (LDLR) family members, the roles of LDLR-related protein (LRP)1 in the pathogenesis of Alzheimer's disease (AD), especially late-onset AD, have been the most studied by genetic, neuropathological, and biomarker analyses (clinical studies) or cellular and animal model systems (preclinical studies) over the last 25 years.Although there are some conflicting reports, accumulating evidence from preclinical studies indicates that LRP1 not only regulates the metabolism of amyloid- peptides (As) in the brain and periphery, but also maintains brain homeostasis, impairment of which likely contributes to AD development in A-independent manners.Several preclinical studies have also demonstrated an involvement of LRP1 in regulating the pathogenic role of apoE, whose gene is the strongest genetic risk factor for AD.Nonetheless, evidence from clinical studies is not sufficient to conclude how LRP1 contributes to AD development.Thus, despite very promising results from preclinical studies, the role of LRP1 in AD pathogenesis remains to be further clarified.In this review, we discuss the potential mechanisms underlying how LRP1 affects AD pathogenesis through A-dependent and -independent pathways by reviewing both clinical and preclinical studies.We also discuss potential therapeutic strategies for AD by targeting LRP1.-Shinohara,M., M. Tachibana, T. Kanekiyo, and G. Bu.Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These pathways highlight how neuronal and glial interactions modulate microglial activity through Apoe, App, Trem2, and Lrp1 [Krasemann et al., 2017; Lin & Holtzman 2024; Shinohara et al., 2017].”
From Cell signaling pathways discovery from multi-modal data (2025) · cites this paper as Shinohara et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lrp1 binds to Apoe-containing lipoproteins and facilitates the endocytosis and degradation of Aβ [Tachibana et al., 2019; Shinohara et al., 2017].”
From Cell signaling pathways discovery from multi-modal data (2025) · cites this paper as Shinohara et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the Apoe-Lrp1 pathway is essential for lipid transport and Aβ clearance across the blood-brain barrier.”
From Cell signaling pathways discovery from multi-modal data (2025) · cites this paper as Shinohara et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“has also been implicated in AD pathology. 21 , 32 , 33”
The cited source says what the claim attributes to it.
In the citing paper
“Cellular receptors such as low-density lipoprotein receptor-related protein 1 (LRP1) [47–50], LRP8 [51], LDLR [52] or RAGE [53] may also affect APP metabolism by either modulating the activities of β- and γ-secretase and/or directly Aβ levels through endocytosis.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
RetractedHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
Flagged first, then by citations
1 of the 184 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Kanekiyo, 2014, The low-density lipoprotein receptor-related protein 1 and amyloid-beta clearance in Alzheimer's disease, Front. Aging Neurosci., 6, 93, 10.3389/fnagi.2014.00093 · DOI · Paper page
Cited by
Sorted by citations
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
LRP1 is a master regulator of tau uptake and spread
Rauch, J. N., Luna, G., Guzman, E., Audouard, M., Challis, C., Sibih, Y. E., Leshuk, C., Hernandez, I., Wegmann, S., Hyman, B. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2156-5 · Cited by 541
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease
Korte, N., Nortley, R., & Attwell, D. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02215-w · Cited by 365
Challenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Zhou, J., Zhang, L., Peng, J., Zhang, X., Zhang, F., Wu, Y., Huang, A., Du, F., Liao, Y., He, Y., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.016 · Cited by 286
The human connectome in Alzheimer disease — relationship to biomarkers and genetics
Yu, M., Sporns, O., & Saykin, A. J. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00529-1 · Cited by 265
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241
Relationship Between Amyloid-β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer’s Disease
Wang, D., Chen, F., Han, Z., Yin, Z., Ge, X., & Lei, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.695479 · Cited by 208
The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives
Wolfe, C. M., Fitz, N. F., Nam, K. N., Lefterov, I. M., & Koldamova, R. P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010081 · Cited by 201
Moulton, M. J., Barish, S., Ralhan, I., Chang, J., Goodman, L. D., Harland, J. G., Marcogliese, P. C., Johansson, J. O., Ioannou, M. S., & Bellen, H. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112095118 · Cited by 180
Cellular cholesterol homeostasis and Alzheimer’s disease
Chang, T.-Y., Yamauchi, Y., Hasan, M. T., & Chang, C. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075630 · Cited by 155
The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome
Drummond, E., Kavanagh, T., Pires, G., Marta-Ariza, M., Kanshin, E., Nayak, S., Faustin, A., Berdah, V., Ueberheide, B., & Wisniewski, T. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01356-1 · Cited by 137
Oxidative stress: The nexus of obesity and cognitive dysfunction in diabetes
Li, H., Ren, J. L., Li, Y., Wu, Q., & Wei, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1134025 · Cited by 163
Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 133
Zhang, Q., Ma, C., Chin, L., & Li, L. (2020) · Science Advances · doi:10.1126/sciadv.abc5802 · Cited by 130
APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread
Chen, Y., Song, S., Parhizkar, S., Lord, J., Zhu, Y., Strickland, M. R., Wang, C., Park, J., Tabor, G. T., Jiang, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.029 · Cited by 120
LRP1 is a neuronal receptor for α-synuclein uptake and spread
Chen, K., Martens, Y. A., Meneses, A., Ryu, D. H., Lu, W., Raulin, A. C., Li, F., Zhao, J., Chen, Y., Jin, Y., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00560-w · Cited by 115
Self-citationVan Gool, B., Storck, S. E., Reekmans, S. M., Lechat, B., Gordts, P. L. S. M., Pradier, L., Pietrzik, C. U., & Roebroek, A. J. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1594-2 · Cited by 114
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 113
Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease
Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02559-z · Cited by 110
TLR Crosstalk Activates LRP1 to Recruit Rab8a and PI3Kγ for Suppression of Inflammatory Responses
Luo, L., Wall, A. A., Tong, S. J. M., Hung, Y., Xiao, Z., Tarique, A. A., Sly, P. D., Fantino, E., Marzolo, M., & Stow, J. L. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.028 · Cited by 97
The Role of Neurovascular System in Neurodegenerative Diseases
Ahmad, A., Patel, V., Xiao, J., & Khan, M. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02023-z · Cited by 97
Resveratrol and Amyloid-Beta: Mechanistic Insights
Jia, Y., Wang, N., & Liu, X. (2017) · Nutrients · doi:10.3390/nu9101122 · Cited by 93
Tachibana, M., Yamazaki, Y., Liu, C., Bu, G., & Kanekiyo, T. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.023 · Cited by 92
Self-citationSeok, H., Lee, M., Shin, E., Yun, M. R., Lee, Y., Moon, J. H., Kim, E., Lee, P. H., Lee, B., Kang, E. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40736-x · Cited by 92
The pathobiology of neurovascular aging
Santisteban, M. M., & Iadecola, C. (2025) · Neuron · doi:10.1016/j.neuron.2024.12.014 · Cited by 102
Candido, S., Lupo, G., Pennisi, M., Basile, M. S., Anfuso, C. D., Petralia, M. C., Gattuso, G., Vivarelli, S., Spandidos, D. A., Libra, M., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7215 · Cited by 86
Alpha-2-Macroglobulin, a Hypochlorite-Regulated Chaperone and Immune System Modulator
Cater, J. H., Wilson, M. R., & Wyatt, A. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5410657 · Cited by 88
Viral Involvement in Alzheimer’s Disease
Sait, A. M., Angeli, C., Doig, A. J., & Day, P. J. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00719 · Cited by 90
Hamdan, A. M. E., Alharthi, F. H. J., Alanazi, A. H., El-Emam, S. Z., Zaghlool, S. S., Metwally, K., Albalawi, S. A., Abdu, Y. S., Mansour, R. E.-S., Salem, H. A., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15081008 · Cited by 82
Chen, Z., Yu, Q., Yu, Q., Johnson, J., Shipman, R. D., Zhong, X., Huang, J., Asthana, S., Carlsson, C. M., Okonkwo, O. C., et al. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100081 · Cited by 84
Targeting Malignant Brain Tumors with Antibodies
Razpotnik, R., Novak, N., Šerbec, V. Č., & Rajčević, U. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01181 · Cited by 80
A Crosstalk Between Brain Cholesterol Oxidation and Glucose Metabolism in Alzheimer’s Disease
Gamba, P., Staurenghi, E., Testa, G., Giannelli, S., Sottero, B., & Leonarduzzi, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00556 · Cited by 77
The emerging role of furin in neurodegenerative and neuropsychiatric diseases
Zhang, Y., Gao, X., Bai, X., Yao, S., Chang, Y., & Gao, G. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00313-1 · Cited by 80
Bres, E. E., & Faissner, A. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00031 · Cited by 73
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease
Bossaerts, L., Cacace, R., & Broeckhoven, C. V. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00536-w · Cited by 56
Xu, M., Wang, J., Zhang, X., Yan, T., Wu, B., Bi, K., & Jia, Y. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112798 · Cited by 56
Wang, Q., Ge, X., Zhang, J., & Chen, L. (2020) · Aging · doi:10.18632/aging.104079 · Cited by 55
Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges
Delaby, C., Hirtz, C., & Lehmann, S. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.09.003 · Cited by 60
Bilousova, T. V., Melnik, M., Miyoshi, E., Gonzalez, B. L., Poon, W. W., Vinters, H. V., Miller, C. A., Corrada, M. M., Kawas, C. H., Hatami, A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.010 · Cited by 57
Mehla, J., Singh, I., Diwan, D., Nelson, J. W., Lawrence, M., Lee, E., Bauer, A. Q., Holtzman, D. M., & Zipfel, G. J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01293-5 · Cited by 52
Cerebrovascular phenotypes in mouse models of Alzheimer’s disease
Szu, J. I., & Obenaus, A. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x21992462 · Cited by 49
Fanaee‐Danesh, E., Gali, C. C., Tadić, J., Zandl‐Lang, M., Kober, A. C., Agujetas, V. R., de Dios, C., Tam‐Amersdorfer, C., Stracke, A., Albrecher, N. M., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.019 · Cited by 53
Single-Cell RNA-Seq Analysis of Olfactory Mucosal Cells of Alzheimer’s Disease Patients
Lampinen, R., Fazaludeen, M. F., Avesani, S., Örd, T., Penttilä, E., Lehtola, J.-M., Saari, T. T., Hannonen, S., Saveleva, L., Kaartinen, E., et al. (2022) · Cells · doi:10.3390/cells11040676 · Cited by 49
Ullah, R., & Lee, E. J. (2023) · Experimental Neurobiology · doi:10.5607/en23014 · Cited by 51
LRP1: A chameleon receptor of lung inflammation and repair
Wujak, L. A., Schnieder, J., Schaefer, L., & Wygrecka, M. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.12.007 · Cited by 48
Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease
Theendakara, V. P., Bredesen, D. E., & Rao, R. V. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.07.002 · Cited by 45
McKee, C. A., Lee, J., Cai, Y., Saito, T., Saido, T. C., & Musiek, E. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-05862-z · Cited by 47
Brain‐targeting drug delivery systems
Liu, P., & Jiang, C. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1818 · Cited by 47
Liu, J., Wang, Z., Liang, W., Zhang, Z., Deng, Y., Chen, X., Hou, Z., Xie, Y., Wang, Q., Li, Y., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.018 · Cited by 47
Spatially resolved gene regulatory and disease-related vulnerability map of the adult Macaque cortex
Lei, Y., Cheng, M., Li, Z., Zhuang, Z., Wu, L. L., Sun, Y., Han, L., Huang, Z., Wang, Y., Wang, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34413-3 · Cited by 47
Zhang, Q., Ma, C., Chin, L., Pan, S., & Li, L. (2024) · Science Advances · doi:10.1126/sciadv.adk6911 · Cited by 47
Zhou, R., Chen, L.-L., Yang, H., Li, L., Liu, J., Chen, L., Hong, W.-J., Wang, C.-G., Ma, J.-J., Huang, J., et al. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210906092940 · Cited by 43
Kim, S. E., Kim, H. J., Jang, H., Weiner, M. W., DeCarli, C. S., Na, D. L., & Seo, S. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810490 · Cited by 42
Neuroprotective Effects of Lactoferrin in Alzheimer’s and Parkinson’s Diseases: A Narrative Review
Yong, S. J., Veerakumarasivam, A., Lim, W. L., & Chew, J. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00679 · Cited by 46
Higginbotham, L. A., Carter, E. K., Dammer, E. B., Haque, R. U., Johnson, E. C. B., Duong, D. M., Yin, L., Jager, P. L. D., Bennett, D. A., Felsky, D., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106286 · Cited by 41
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 46
Focused ultrasound mitigates pathology and improves spatial memory in Alzheimer's mice and patients
Karakatsani, M. E., Ji, R., Murillo, M. F., Kugelman, T., Kwon, N., Lao, Y., Liu, K., Pouliopoulos, A. N., Honig, L. S., Duff, K., et al. (2023) · Theranostics · doi:10.7150/thno.79898 · Cited by 49
Kirchner, K., Garvert, L., Kühn, A. L., Bonk, S., Grabe, H. J., & der Auwera, S. V. (2023) · Cells · doi:10.3390/cells12212512 · Cited by 40
Knockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake
La‐Rocque, S. D., Moretto, E., Butnaru, I., & Schiavo, G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15144 · Cited by 46
Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease
Pons, V., & Rivest, S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000400 · Cited by 41
Marcatti, M., Fracassi, A., Montalbano, M., Natarajan, C., Krishnan, B., Kayed, R., & Taglialatela, G. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04255-9 · Cited by 38
Comprehensive Overview of Alzheimer’s Disease: Etiological Insights and Degradation Strategies
Singh, M. K., Shin, Y., Ju, S., Han, S., Kim, S. S., & Kang, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136901 · Cited by 43
Al-Atrache, Z., Lopez, D. B., Hingley, S. T., & Appelt, D. M. (2019) · BMC Neuroscience · doi:10.1186/s12868-019-0489-5 · Cited by 37
SCO-spondin, a giant matricellular protein that regulates cerebrospinal fluid activity
Sepúlveda, V., Maurelia, F., González, M., Aguayo, J., & Caprile, T. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00277-w · Cited by 45
The ABC's of Alzheimer risk gene ABCA7
Duchateau, L., Wawrzyniak, N., & Sleegers, K. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13805 · Cited by 35
Hsu, H.-W., Rodríguez‐Ortiz, C. J., Lim, S., Zumkehr, J., Kilian, J., Vidal, J., & Kitazawa, M. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz084 · Cited by 36
Promoter DNA hypermethylation – Implications for Alzheimer’s disease
Liu, Y., Wang, M., Marcora, E. M., Zhang, B., & Goate, A. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134403 · Cited by 37
Long non-coding RNAs in neurodegenerative diseases
Yang, S., Yang, H., Luo, Y., Deng, X., Zhou, Y., & Hu, B. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105096 · Cited by 33
Molecular mechanisms underlying actions of certain long noncoding RNAs in Alzheimer’s disease
Ahmadi, S., Zobeiri, M., & Bradburn, S. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00564-9 · Cited by 35
LncRNAs as the Regulators of Brain Function and Therapeutic Targets for Alzheimer’s Disease
Liu, Y., Chen, X., Che, Y., Li, H., Zhang, Z., Peng, W., & Yang, J. (2022) · Aging and Disease · doi:10.14336/ad.2021.1119 · Cited by 35
Bracher-Smith, M., Leonenko, G., Baker, E., Crawford, K., Graham, A. C., Salih, D. A., Howell, B. W., Hardy, J., & Escott-Price, V. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.07.009 · Cited by 31
APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33
Liu, A., Fernandes, B. S., Citu, C., & Zhao, Z. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01372-w · Cited by 34
Solé, M., Esteban-López, M., Taltavull, B., Fábregas, C., Fadó, R., Casals, N., Rodríguez-Álvarez, J., Miñano-Molina, A. J., & Unzeta, M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.016 · Cited by 34
Thymosin β4 protects against aortic aneurysm via endocytic regulation of growth factor signaling
Munshaw, S., Bruche, S., Redpath, A. N., Jones, A. N., Patel, J., Dubé, K. N., Lee, R., Hester, S. S., Davies, R., Neal, G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci127884 · Cited by 34
Peripheral amyloid-β clearance mediates cognitive impairment in non-alcoholic fatty liver disease
Peng, X., Zhang, X., Xu, Z., Li, L., Mo, X., Peng, Z., Shan, Z., Yan, H., Xu, J., & Liu, L. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105079 · Cited by 35
Wang, Q., & Zuo, Z. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1513493 · Cited by 32
Gadhave, K., Gehi, B. R., Kumar, P., Xue, B., Uversky, V. N., & Giri, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03414-9 · Cited by 35
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Single-cell RNA sequencing in atherosclerosis: Mechanism and precision medicine
Li, Q., Wang, M., Zhang, S., Jin, M., Chen, R., Luo, Y., & Sun, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977490 · Cited by 29
Role of astrocytes in sleep deprivation: accomplices, resisters, or bystanders?
Que, M., Li, Y., Wang, X., Zhan, G., Luo, X., & Zhou, Z. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1188306 · Cited by 35
Somatostatin and the pathophysiology of Alzheimer’s disease
Almeida, V. N. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102270 · Cited by 31
Prediction of Alzheimer’s disease with serum lipid levels in Asian individuals: a meta-analysis
Wu, Y., Wang, Z., Jia, X., Zhang, H., Zhang, H., Li, J., & Zhang, K. (2019) · Biomarkers · doi:10.1080/1354750x.2019.1571633 · Cited by 31
Hao, W., Luo, Q., Tomic, I., Quan, W., Hartmann, T., Menger, M. D., Fassbender, K. C., & Liu, Y. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2363014 · Cited by 29
Yue, X., Zhou, Y., Qiao, M., Zhao, X., Huang, X. H., Zhao, T., Cheng, X., Fan, M., Zhao, Y., Chen, R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00935-z · Cited by 30
Dafnis, I., Raftopoulou, C., Mountaki, C., Megalou, E. V., Zannis, V. I., & Chroni, A. (2018) · Biochemical Journal · doi:10.1042/bcj20180068 · Cited by 29
Is It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
Mao, Y., Fisher, D. W., Yang, S., Keszycki, R. M., & Dong, H. (2020) · PLOS ONE · doi:10.1371/journal.pone.0226021 · Cited by 28
Proteins in the pathway from high red blood cell width distribution to all-cause mortality
Osawa, Y., Tanaka, T., Semba, R. D., Fantoni, G., Moaddel, R., Candia, J., Simonsick, E. M., Bandinelli, S., & Ferrucci, L. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103816 · Cited by 27
Pilat, D., Paumier, J.-M., García-González, L., Louis, L., Stephan, D., Manrique, C., Khrestchatisky, M., Di Pasquale, E., Baranger, K., & Rivera, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02407-z · Cited by 28
Tegowski, M., Prater, A. K., Holley, C. L., & Meyer, K. D. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01768-3 · Cited by 27
The Roles of Apolipoprotein E, Lipids, and Glucose in the Pathogenesis of Alzheimer’s Disease
Shinohara, M., & Sato, N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_5 · Cited by 28
Self-citationTargeting Wnt signaling pathway by polyphenols: implication for aging and age-related diseases
Dana, P. M., Sadoughi, F., Mansournia, M. A., Mirzaei, H., Asemi, Z., & Yousefi, B. (2021) · Biogerontology · doi:10.1007/s10522-021-09934-x · Cited by 27
Oue, H., Yamazaki, Y., Qiao, W., Yuanxin, C., Ren, Y., Kurti, A., Shue, F., Parsons, T. M., Perkerson, R. B., Kawatani, K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163822 · Cited by 26
Self-citation
Metadata
- Authors
- Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Shinohara, Mitsuru
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 58
- Issue
- 7
- Pages
- 1267-1281
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC5496044
- OpenAlex
- W2605039207
- Cited by
- 297
- References
- 184
- Citations by year
- 2026: 30 · 2025: 51 · 2024: 44 · 2023: 37 · 2022: 38 · 2021: 38 · 2020: 25 · 2019: 20 · 2018: 7 · 2017: 7
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (P50AG016574, RF1AG051504, R01AG027924, R01AG035355, R01AG046205, P01NS074969)
- Cure Alzheimer’s Fund
- Naito Foundation
- BrightFocus Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- LRP1, Alzheimer's disease, LDL receptor family, amyloid-beta metabolism, APOE ε4, late-onset Alzheimer's disease, amyloid-beta deposition, neuroinflammation, neurodegeneration, brain homeostasis, APOE ε4 carriers
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Humans, Biomarkers, Amyloid beta-Peptides, Low Density Lipoprotein Receptor-Related Protein-1, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
